MX2021013360A - Rebamipida para usarse en la prevencion y/o tratamiento de sinucleinopatias. - Google Patents

Rebamipida para usarse en la prevencion y/o tratamiento de sinucleinopatias.

Info

Publication number
MX2021013360A
MX2021013360A MX2021013360A MX2021013360A MX2021013360A MX 2021013360 A MX2021013360 A MX 2021013360A MX 2021013360 A MX2021013360 A MX 2021013360A MX 2021013360 A MX2021013360 A MX 2021013360A MX 2021013360 A MX2021013360 A MX 2021013360A
Authority
MX
Mexico
Prior art keywords
rebamipide
prevention
treatment
synucleinopathies
synucleinopathy
Prior art date
Application number
MX2021013360A
Other languages
English (en)
Inventor
Ivan Danek
Original Assignee
Square Power Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Square Power Ltd filed Critical Square Power Ltd
Publication of MX2021013360A publication Critical patent/MX2021013360A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona rebamipida para usarse en un método de prevención y/o tratamiento de una sinucleinopatía, en particular de la enfermedad de Parkinson; en particular, la rebamipida se usa en la prevención y/o tratamiento de una sinucleinopatía en una persona que padece un aumento de la permeabilidad intestinal o en una persona que corre el riesgo de un aumento de la permeabilidad intestinal.
MX2021013360A 2019-04-30 2020-04-30 Rebamipida para usarse en la prevencion y/o tratamiento de sinucleinopatias. MX2021013360A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19020318.2A EP3741370A1 (en) 2019-04-30 2019-04-30 Rebamipide for use in prevention and/or treatment of synucleinopathies
PCT/EP2020/062120 WO2020221892A2 (en) 2019-04-30 2020-04-30 Rebamipide for use in prevention and/or treatment of synucleinopathies

Publications (1)

Publication Number Publication Date
MX2021013360A true MX2021013360A (es) 2022-01-31

Family

ID=66396957

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013360A MX2021013360A (es) 2019-04-30 2020-04-30 Rebamipida para usarse en la prevencion y/o tratamiento de sinucleinopatias.

Country Status (12)

Country Link
US (1) US20220202805A1 (es)
EP (1) EP3741370A1 (es)
JP (1) JP2022533005A (es)
KR (1) KR20220003064A (es)
CN (1) CN113784715A (es)
AU (1) AU2020266279A1 (es)
BR (1) BR112021021681A2 (es)
CA (1) CA3138389A1 (es)
EA (1) EA202192961A1 (es)
MX (1) MX2021013360A (es)
WO (1) WO2020221892A2 (es)
ZA (1) ZA202110052B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112603899A (zh) * 2020-12-23 2021-04-06 南京友杰医药科技有限公司 瑞巴派特肠溶片及其制备方法

Also Published As

Publication number Publication date
WO2020221892A3 (en) 2020-12-24
US20220202805A1 (en) 2022-06-30
EA202192961A1 (ru) 2022-01-20
WO2020221892A2 (en) 2020-11-05
JP2022533005A (ja) 2022-07-21
CA3138389A1 (en) 2020-11-05
EP3741370A1 (en) 2020-11-25
KR20220003064A (ko) 2022-01-07
AU2020266279A1 (en) 2021-12-23
ZA202110052B (en) 2023-11-29
BR112021021681A2 (pt) 2021-12-21
CN113784715A (zh) 2021-12-10

Similar Documents

Publication Publication Date Title
MX2020013808A (es) Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
PH12021550882A1 (en) Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
MX2017014547A (es) Secuencias de uricasa mejoradas y metodos de tratamiento.
EA201892803A1 (ru) Противоопухолевая терапия
PH12018502297A1 (en) 9-aminomethyl minocycline compounds and methods of use thereof in urinary tract infection (uti) treatment
MX2019015212A (es) Compuestos para el tratamiento del sarcoma.
MX2022014034A (es) Métodos para tratar covid-19 con el uso de bardoxolona metilo o análogos de esta.
IL285452A (en) A new recombinant diamine oxidase and its use in the treatment of diseases characterized by excess histamine
IL283666A (en) A method for identifying, preventing, reversing and treating neurological diseases
EP4028021C0 (fr) Utilisation de nmn pour la prévention et/ou le traitement de la douleur et compositions correspondantes
ZA202110052B (en) Rebamipide for use in prevention and / or treatment of synucleinopathies
ZA202206308B (en) Ezetimibe and curcumin for use in cancer treatment
MX2017005522A (es) Tratamiento novedoso de la cornea usando laminina.
MX2021003160A (es) Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama.
MX2022002629A (es) Rebamipida para usarse en la prevencion y tratamiento de la enfermedad de crohn.
MX2022002625A (es) Rebamipida para usarse en la profilaxis y tratamiento de enfermedad celiaca.
MX2021009670A (es) Tratamiento para el cancer.
MX2021001228A (es) Composicion para uso en la prevencion y/o tratamiento de la mucosa genitourinaria.
EP4234022A3 (en) Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
MX2022013883A (es) Compuestos de metiltioninio para uso en el tratamiento de covid-19.
ZA202203504B (en) Rebamipide for use in prophylaxis and treatment of cancer
WO2020097442A3 (en) Compositions and methods for the treatment of peripheral artery disease and cardiopulmonary diseases
MX2021011183A (es) Fitoecdisonas y los derivados de las mismas para su uso en el tratamiento de la alteracion de la funcion respiratoria.
CR20220071A (es) Composiciones farmacéuticas y métodos para tratar o prevenir la atrofia muscular espinal
EP3669880A4 (en) USE OF miR-18b IN THE PREVENTION, TREATMENT, OR DIAGNOSIS OF MUSCLE AND NEUROMUSCULAR DISEASE